Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythematosus Patients: A Randomized Clinical Trial Study

Authors

  • Fiblia Fiblia Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Iris Rengganis Division of Allergy Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia -Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Dyah Purnamasari Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Alvina Widhani Division of Allergy Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia -Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Teguh H Karjadi Division of Allergy Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia -Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Hamzah Shatri Division of Psychosomatics and Palliative Care, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Rudi Putranto Division of Psychosomatics and Palliative Care, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia

Keywords:

cholecalciferol, disease activity, quality of life, systemic lupus erythematosus

Abstract

Background: Increase in the prevalence and survival rates has led to the assessment of disease activity and quality of life of SLE patients as targets in treatment. Cholecalciferol was considered as having a role in reducing disease activity and improving quality of life. Methods: A double blind, randomized, controlled trial was conducted on female  outpatients aged 18-60 years with SLE, consecutively recruited from September to December 2021 at Cipto Mangunkusumo Hospital. Sixty subjects who met the research criteria were randomized and equally assigned into the cholecalciferol and placebo groups. The study outcomes were measured at baseline and after 12 weeks of intervention. Results: Out of 60 subjects, 27 subjects in cholecalciferol group and 25 subjects in placebo group completed the intervention. There was a significant improvement on the level of vitamin D (ng/ml) after intervention in the cholecalciferol group, from an average of 15,69 ng/ml (8.1-28.2) to 49,90 ng/ml (26-72.1), and for the placebo group from 15,0 ng/ml (8.1-25,0) to 17.35 ng/ml (8.1-48.3) (p<0,000). Results of the MEX-SLEDAI score showed significant differences in both groups after the intervention, with a significant decrease in the cholecalciferol group from 2,67 (0-11) to 1,37 (0-6), compared to the placebo group from 2,6 (0-6) to  2,48 (0-6) (p<0,001). There were no significant differences on the quality of life in both groups. Conclusion: Supplementation of cholecalciferol 5000 IU/day for 12 weeks was statistically significant in increasing vitamin D levels and improving disease activity, but did not significantly improve the quality of life of SLE patients.

Author Biographies

Iris Rengganis, Division of Allergy Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia -Cipto Mangunkusumo Hospital, Jakarta, Indonesia

allergy immunology internal medicine

Dyah Purnamasari, Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia

Endocrinology and metabolic internal medicine

Alvina Widhani, Division of Allergy Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia -Cipto Mangunkusumo Hospital, Jakarta, Indonesia

Allergy and immunology internal medicine

Teguh H Karjadi, Division of Allergy Immunology, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia -Cipto Mangunkusumo Hospital, Jakarta, Indonesia

Allergy and immunology Internal medicine

Hamzah Shatri, Division of Psychosomatics and Palliative Care, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia

Psychosomatic internal medicine

Rudi Putranto, Division of Psychosomatics and Palliative Care, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia

Psychosomatic Intenal medicine

References

Bertsias G RC. SLE pathogenesis and clinical feature. eular-fpp-indd. 2012;36(12):1503.

Olesińska M, Saletra A. Quality of life in systemic lupus erythematosus and its measurement. 2018;45–54.

Buleu F, Gurban C, Sarbu E, et al. The relationship between vitamin D, inflammation and the activity of systemic lupus erythematosus. Fiziol - Physiol. 2015;25(November):87.

Nguyen MH, Bryant K, O’Neill SG. Vitamin D in SLE: a role in pathogenesis and fatigue? A review of the literature. Lupus. 2018;27(13):2003–11.

Antico A, Tampoia M, Tozzoli R, Bizzaro N. Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. Autoimmun Rev [Internet]. 2012;12(2):127–36.

Christie M, Bartels HSD. Systemic lupus erythematosus (SLE). Medscape [Internet]. 2020;2(2):2319–6718.

Hassanalilou1 T, Khalili L, Ghavamzadeh S, et al. Role of vitamin D defciency in systemic lupus erythematosus incidence and aggravation. Autoimmun Highlights. 2018;9(1):890–4.

Hassanalilou T, Khalili L, Ghavamzadeh S, et al. Role of vitamin D defciency in systemic lupus erythematosus incidence and aggravation. Autoimmun Highlights [Internet]. 2018;9(1):1–10.

Schoindre Y, Jallouli M, Tanguy ML, et al. Lower vitamin D levels are associated with higher systemic lupus erythematosus activity, but not predictive of disease flare-up. Lupus Sci Med. 2014;1(1):1–8.

Rifaâi, Kusworini A, Kusworini HKSW. Effect of vitamin D supplementation on disease activity (SLEDAI) and fatigue in Systemic Lupus Erythematosus patients with hipovitamin D: An Open Clinical Trial. Indones J Rheumatol. 2008;8(2):501–7.

Lomarat W, Narongroeknawin P, Chaiamnuay S, Asavatanabodee P. Randomized double-blind controlled trial to evaluate efficacy of vitamin d supplementation among patients. 2020;7980:24–32.

Fisher SA, Rahimzadeh M, Brierley C, et al. The role of vitamin D in increasing circulating T regulatory cell numbers and modulating T regulatory cell phenotypes in patients with inflammatory disease or in healthy volunteers: A systematic review. PLoS One. 2019;14(9):1–18.

McElhone K, Abbott J, Teh LS. A review of health related quality of life in systemic lupus erythematosus. Lupus. 2006;15(10):633–43.

Lima GL, Paupitz J, Aikawa NE, Takayama L, Bonfa E, Pereira RMR. Vitamin D supplementation in adolescents and young adults with juvenile systemic lupus erythematosus for improvement in disease activity and fatigue scores: a randomized, double-blind, placebo-controlled trial. Arthritis Care Res. 2016;68(1):91–8.

Downloads

Published

2022-09-24

How to Cite

Fiblia, F., Rengganis, I., Purnamasari, D., Widhani, A., Karjadi, T. H., Shatri, H., & Putranto, R. (2022). Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythematosus Patients: A Randomized Clinical Trial Study. Acta Medica Indonesiana, 54(3), 406. Retrieved from https://www.actamedindones.org/index.php/ijim/article/view/2074